Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
France Targets Shein, Temu With Fast-Fashion Fees 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Milei Threatens Falkland Oil Firms With Sanctions 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Add as a preferred source on Google
BRIDGEWATER, N.J., March 07, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that a member of the management team will present at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Wednesday, March 14, 2018 at 10:40 a.m. ET.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical Company focused on the unmet needs of patients with rare diseases. The Company’s lead product candidate is ALIS, which is in late-state development for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
[email protected]
